CAPTRUST Financial Advisors
INKT icon

CAPTRUST Financial Advisors’s MiNK Therapeutics INKT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,532
Closed -$11.5K – 2347
2024
Q3 		$11.5K Sell
1,532
-2,041
-57% -$17.3K ﹤0.01% 2271
2024
Q2 		$33.9K Sell
3,573
-1,856
-34% -$18.1K ﹤0.01% 2163
2024
Q1 		$49.3K Hold
5,429
– – ﹤0.01% 2087
2023
Q4 		$58.1K Sell
5,429
-751
-12% -$7.84K ﹤0.01% 2579
2023
Q3 		$68K Buy
6,180
+2,226
+56% +$36.2K ﹤0.01% 2458
2023
Q2 		$83K Buy
+3,954
New +$79.2K ﹤0.01% 2396

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CAPTRUST Financial Advisors's INKT Position: Q4 2024 in Review

CAPTRUST Financial Advisors sold out of MiNK Therapeutics (INKT) in Q4 2024, closing a stake of 1,532 shares — an estimated $11.5K sold.

CAPTRUST Financial Advisors first reported a position in INKT in Q2 2023 and held it in 6 quarters. The position peaked at $83K in Q2 2023. 21 funds tracked by Wall St. Rank hold INKT as of Q4 2024.

  • CAPTRUST Financial Advisors reported no remaining MiNK Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,532 MiNK Therapeutics shares in Q4 2024, an estimated $11.5K.
  • CAPTRUST Financial Advisors first reported a position in MiNK Therapeutics in Q2 2023 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's MiNK Therapeutics position peaked at $83K in Q2 2023.
  • 21 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q4 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.